Sempra (NYSE:SRE) Q4 2025 Earnings call February 26, 2026 12:00 PM ET Company ParticipantsAllen Nye - CEOJeff Martin - Chairman and CEOKaren Sedgwick - EVP and CFOLouise Bick - VP of Investor RelationsShar Pourreza - Managing Director and Head of North American Power, Infrastructure and UtilitiesConference Call ParticipantsAidan Kelly - Equity Research AnalystAnthony Crowdell - Managing Director and Senior Equity Research AnalystCarly Davenport - VP and Equity Research AnalystDavid Arcaro - Executive Direct ...

Henry Schein (NasdaqGS:HSIC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker11As a reminder, this call is being recorded. I would now like to introduce you to your host for today's call, Graham Stanley, Henry Schein's Vice President of Investor Relations and Strategic Financial Project Officer. Please go ahead, Graham.Speaker4Thank you, operator, and thanks to each of you for joining us today to discuss Henry Schein's financial results for the fourth quarter of 2025. With me on today's call is S ...

Financial Data and Key Metrics Changes - In Q4 2025, the company reported sales of $751 million, with core sales increasing by 10.8% year-over-year, benefiting from foreign exchange (FX) which added nearly 400 basis points [15][19] - Adjusted EBITDA margin for Q4 was 14.8%, a 90 basis point improvement from the previous year, driven by volume, price, and productivity [16][21] - Adjusted EPS for Q4 was $0.38, up more than 50% from Q4 2024, supported by strong operating profits and share repurchases [13][16] - For the full year 2025, sales reached $2.7 billion, with core sales increasing by 6.5% [17][18] - Adjusted EBITDA for 2025 was up 26%, resulting in a margin of around 14%, a 2-point improvement over 2024 [13][18] Business Line Data and Key Metrics Changes - Specialty products and technologies revenue grew nearly 16% year-over-year, with core sales up 10.9% [22] - The orthodontics business, including Spark, saw high single-digit growth, with brackets and wires up double digits year-over-year [22][24] - The implants segment grew mid-single digits globally, with strong performance in digital and regenerative segments [22] - Equipment and consumables segment core sales increased by 10.7%, with diagnostics core sales up double digits globally [24] Market Data and Key Metrics Changes - The North American diagnostic market returned to growth in the second half of 2025, marking the third consecutive quarter of positive growth across all business lines [31][32] - The overall implant market is estimated to be growing mid-single digits, with the company slightly outperforming this in Q4 [70] Company Strategy and Development Direction - The company is focused on a value creation plan aimed at achieving 2%-4% core growth, 4%-7% EBITDA growth, and 7%-10% EPS growth, with a free cash flow conversion target of 100% or better [7][14] - Continued investment in R&D and new product launches is a priority, with a strong pipeline for 2026 [12][31] - The company aims to maintain its competitive edge by enhancing customer training and product offerings [71] Management's Comments on Operating Environment and Future Outlook - Management noted that the dental market remains slow but stable, with signs of improvement beginning to emerge [31][32] - The company expects core revenue growth of 2%-4% for 2026, aligning with medium-term financial objectives [14][26] - Risks include macroeconomic volatility and uncertainties in the Chinese market, particularly regarding value-based pricing (VBP) [41][54] Other Important Information - The company implemented a $250 million share repurchase program in early 2025, returning over $160 million to shareholders throughout the year [9][25] - Free cash flow for 2025 was $231 million, with a conversion rate of 114% [25] Q&A Session Summary Question: Guidance and potential upsides/risks - Management discussed the guidance for 2026, highlighting potential upsides from market momentum and pricing, while noting risks from macro volatility and the Chinese market [35][41] Question: Tax rate expectations - The expected non-GAAP tax rate for 2026 is around 28%, with potential for further reductions depending on U.S. profitability and debt management [47][49] Question: VBP assumptions for ortho and implants - Management expects first-round VBP for ortho and second-round for implants in 2026, but specific timing remains uncertain [52][54] Question: Spark growth and profitability - Spark continues to outgrow the market, with profitability consistent with previous quarters, driven by new product introductions and customer training [78]

Summary of Envista's Conference Call Company Overview - **Company**: Envista Holdings Corporation - **Industry**: Dental MedTech - **Market Size**: Approximately $400 billion in annual spend, making it a significant healthcare category [4][12] Core Points and Arguments Growth and Financial Performance - **Organic Growth**: Envista reported a 5% organic growth year-to-date through Q3 2025, with all major businesses showing two consecutive quarters of positive growth [3][19] - **EBITDA and EPS Growth**: Strong double-digit growth in both EBITDA and EPS was noted, indicating robust financial health [4][22] - **Value Creation Plan**: The plan focuses on three priority areas: growth, operations, and people, with medium-term financial objectives of 2-4% organic revenue growth, 4-7% EBITDA growth, and 7-10% EPS growth [16][17] Market Dynamics - **Demand vs. Supply**: Demand for dental services is high, but supply constraints, such as the number of licensed clinicians, limit long-term market growth [5][6] - **Market Resilience**: The dental market has shown resilience, consistently outpacing GDP growth, even during economic downturns [12][14] - **Post-COVID Recovery**: After a significant contraction during COVID-19, the dental market is expected to return to a consistent growth rate of 3-5% [14][24] Strategic Focus Areas - **Product Innovation**: Envista has a strong focus on new product development, holding over 1,500 patents and having introduced significant innovations in dental technology [9][10] - **Specialty Categories**: The company emphasizes specialty categories that are sold directly to clinicians, which typically yield better margins and growth rates [11][12] - **Geographic Distribution**: Approximately half of Envista's sales come from the U.S., with the remainder spread across Europe and developing markets [9] Operational Efficiency - **Envista Business System**: The company employs a continuous improvement methodology focusing on safety, quality, and customer service, which contributes to operational efficiency [3][18] - **Cost Management**: G&A spending was reduced by 12% in the first quarters of last year, contributing to improved profitability [20][45] Employee Engagement and Community Investment - **Talent Development**: The company has renewed its focus on promoting from within, with over 50% of management promotions going to existing employees [21] - **Community Engagement**: The Envista Smile Project provided care to 19,000 underserved patients and donated over $2 million last year [21] Additional Important Insights - **Interest Rates Impact**: Lowering interest rates are expected to support dental market growth, particularly for multi-site operators and equipment purchases [27][28] - **Revenue Recognition Changes**: Changes in revenue recognition for the Spark business impacted reported revenues but are expected to normalize by Q2 2026 [30][32] - **Value-Based Pricing (VBP) in China**: The Chinese government is expected to implement further rounds of VBP, which could significantly impact Envista's market share and unit sales in the region [39][40] Conclusion - Envista is positioned as a leader in the dental MedTech market, with a solid growth strategy and operational efficiencies. The company is optimistic about returning to pre-COVID growth rates and is actively investing in innovation and community engagement to drive future success [24][49]

Summary of Henry Schein FY Conference Call - December 02, 2025 Company Overview - **Company**: Henry Schein (NasdaqGS: HSIC) - **Industry**: Dental and Medical Distribution Key Points Leadership and Company Performance - Stanley Bergman, the Chairman and CEO, reflected on the company's journey over the past five years, highlighting the impact of COVID-19 on the dental and medical businesses, including a significant increase in PPE sales during the pandemic [4][5][6] - The company faced a cyber incident in October 2023 but managed to recover without paying ransom, which allowed them to stabilize operations [5][6] - The "Bold plus One" initiative has successfully diversified income towards high-growth, high-margin products, now accounting for about 50% of the company's profits, up from approximately 30% [7] Succession Planning - The board is conducting a thorough search for a new CEO, with both internal and external candidates being considered [9][10] KKR Investment - KKR increased its stake in Henry Schein from 12% to 15%, with the potential to reach 20%. The partnership has been beneficial, with KKR adding experienced board members [11][12][14] Market Conditions - The dental market is currently characterized as "stable plus," with patient traffic remaining steady and some growth observed in specialty areas [16][17] - The company reported strong growth in Q3, the highest in many quarters, as they focused on customer recovery post-cyber incident [18][19] Pricing and Tariffs - Tariffs are expected to remain, but their impact on pricing has been manageable. The company has seen some price inflation but believes the market is stable [21][22][23] - Henry Schein offers a broad portfolio of branded and private label products, which helps mitigate tariff impacts [24][26] Future Guidance and Growth - The company aims for high single to low double-digit earnings growth in the future, with a focus on market share gains and value creation initiatives expected to yield over $200 million in operating income improvements by 2026 [27][29][30] - The restructuring plan initiated in 2024 is expected to complement value creation initiatives, leading to additional savings [31] Specialty Franchises and EBIT Goals - The goal is to achieve over 50% of EBIT from higher-margin specialty categories, with current figures around 45% [32][34] Relationships with Manufacturers and DSOs - Relationships with manufacturers are stable, and the company continues to maintain good partnerships with Dental Service Organizations (DSOs) [36][38] - Henry Schein emphasizes its comprehensive solutions, which include not just products but also services that enhance operational efficiency for dental practices [39][45] Equipment Market Outlook - The dental equipment market is expected to grow, driven by new practices opening and existing practices seeking efficiency through digital solutions [48][49] - Despite potential price declines in mature technologies, volume growth is anticipated to compensate for this [50] Excitement for 2026 - The focus for 2026 will be on providing clinical solutions that enhance practice efficiency and improve patient care, with an emphasis on integrating various technologies [51][52] Additional Insights - The company is positioned as a key player in the dental market, leveraging its extensive network and solutions to maintain a competitive edge [37][45]

Financial Data and Key Metrics Changes - Global sales for the third quarter were $3.3 billion, reflecting a sales growth of 5.2% compared to the third quarter of 2024, with constant currency sales growth of 4.0% [17][22] - GAAP operating margin for the third quarter was 4.88%, a decrease of six basis points year-over-year, while non-GAAP operating margin increased to 7.83%, up 19 basis points [18][19] - Third quarter GAAP net income was $101 million, or $0.84 per diluted share, compared to $99 million, or $0.78 per diluted share in the prior year [20] - Non-GAAP net income for the third quarter was $167 million, or $1.38 per diluted share, compared to $155 million, or $1.22 per diluted share in the prior year [20] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 4.8%, with U.S. dental merchandise sales increasing by 3.3% and U.S. dental equipment sales growing by 1.2% [22] - Global specialty products group sales grew by 5.9%, with strong performance in implants and biomaterials, particularly in the value segment [23][12] - Global technology group sales grew by 9.7%, driven by practice management software and revenue cycle management solutions [23][14] Market Data and Key Metrics Changes - U.S. medical distribution sales grew by 4.7%, reflecting strong demand for medical products, particularly in the dialysis business [10][22] - International dental merchandise sales grew by 6.0%, driven by sales growth in Brazil, Canada, Italy, Spain, and Australia [22] - International implant sales increased by high single digits, particularly in the Dutch region and Latin America [13] Company Strategy and Development Direction - The company is focused on executing the BOLD+1 strategy, aiming for over 50% of non-GAAP operating income to come from high-growth, high-margin businesses by the end of 2027 [8][6] - A $750 million increase in the share repurchase program was approved, with expectations to continue buybacks at a similar pace [8][25] - The company is rolling out a new global e-commerce platform, with a phased launch in North America expected to follow the successful launch in the U.K. and Ireland [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to high single-digit to low double-digit earnings growth, supported by ongoing value creation initiatives [7][24] - The cyber incident is now behind the company, allowing sales teams to focus on growth [39][6] - The management team remains optimistic about the future, emphasizing the importance of customer partnerships and innovation [32][33] Other Important Information - The company recorded restructuring expenses of $34 million during the third quarter, with expectations of achieving annual run-rate savings of over $100 million from the restructuring program [24] - The effective tax rate for the third quarter was 22.9%, lower than the previous year's rate of 24.9% [20] Q&A Session Summary Question: Future earnings growth and restructuring benefits - Management indicated that the $200 million operating income improvement is a multi-year plan, with some benefits expected in 2026 [40][41] Question: Clarification on EPS guidance and market conditions - The midpoint of 2025 EPS guidance increased by $0.05, reflecting momentum in sales growth and a remeasurement gain [44][46] Question: Specialty products operating profit and margin dynamics - Specialty products operating profit was impacted by a strong prior-year comparison and a shift in sales mix towards lower-margin value implants [66][67] Question: Growth trajectory for specialty products - Continued growth in premium implants and improvements in endodontics are necessary for EBIT growth in the specialty business [70][71] Question: Share gains and market conditions - Management noted stable market conditions with some share gains, particularly in the dental and medical sectors [51][52]

Financial Data and Key Metrics Changes - Q3 revenue was $623 million, essentially flat compared to the same period last year, bringing year-to-date revenue to $1.84 billion [17] - The third quarter net loss was $28 million, an improvement driven by higher foreign exchange gains and the absence of a non-cash impairment charge recorded last year [17] - Adjusted diluted EPS was flat sequentially at $0.18, with changes attributed to the divestiture of ScholarOne [17] - Free cash flow was $115 million in Q3, totaling $276 million year-to-date, driven by adjusted EBITDA and working capital [22] Business Line Data and Key Metrics Changes - The A&G segment saw a 2% ACV growth, with a subscription mix now at 93% compared to 81% last year [7][8] - The Intellectual Property segment's recurring revenue was flat year-to-date, representing a 3% improvement in organic growth compared to the full year of 2024 [9] - Life Sciences and Health segment returned to 2% ACV growth, driven by new product introductions and AI integration [11] Market Data and Key Metrics Changes - The company secured over 100 contracts for its new content subscription framework, indicating strong market demand [8] - Renewal rates in Life Sciences and Health improved to 93%, up 100 basis points year-over-year [5] - The U.S. dollar remained weaker against foreign currencies, providing a foreign exchange tailwind on revenue [20] Company Strategy and Development Direction - The company is focused on executing its value creation plan, emphasizing product and AI development to drive organic growth [6][14] - Plans to streamline the business model and market focus include exiting A&G transactional books and the Life Sciences Real World Data Resell Market [15] - The company aims to enhance its core subscription and recurring revenue mix to improve predictability, achieving an 8% improvement this year compared to last year [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning the Intellectual Property segment to sustainable growth under new leadership [9][35] - The company anticipates continued acceleration in organic annual contract value and expects to raise revenue guidance by $50 million [24] - Management believes that operational efficiency and margin expansion will be achieved through the adoption of agentic AI [14] Other Important Information - The company has completed $150 million in share repurchases year-to-date and paid down $100 million in debt [5][23] - The strategic disposals are expected to lower revenue by approximately $90 million this year, with a similar impact anticipated next year [28] Q&A Session Summary Question: Insights on the patent renewal business and competitive landscape - Management noted that the patent and trademark renewal service declined by about 3% last year but is now flat year-to-date, with expectations for improvement under new leadership [35][36] Question: Updates on new innovations in the value creation plan - Management highlighted the introduction of AI-enabled products and a renewed focus on product innovation, with several new products expected to drive growth [41][42] Question: Impact of large ebook transactions on revenue and EBITDA - Management indicated that multiple large ebook transactions positively impacted revenue, with expectations for a decline in that area moving forward [47] Question: Potential of the business after strategic changes - Management expressed optimism about returning to market growth rates of 3-4% over time, citing strong fundamentals and a supportive customer base [48][49] Question: ACV acceleration and segment contributions - Management noted improvements across all segments, particularly in Life Sciences, with expectations for continued growth in the IP segment [55] Question: Trends in patents and trademarks - Management observed a gradual increase in patents in force and anticipated a recovery in volumes driven by innovation, particularly in AI [61][62] Question: Transactional revenues and their impact on guidance - Management explained that slower attrition of disposals contributed to improved revenue guidance, with a significant portion of revenue expected to decline next year [72]

Financial Data and Key Metrics Changes - Q3 revenue was $623 million, essentially flat compared to the same period last year, bringing year-to-date revenue to $1.84 billion [17] - The third quarter net loss was $28 million, an improvement driven by higher foreign exchange gains and the absence of a non-cash impairment charge recorded last year [17] - Adjusted diluted EPS was flat sequentially at $0.18, with changes attributed to the divestiture of ScholarOne [17] - Free cash flow was $115 million in Q3, totaling $276 million year-to-date, driven by adjusted EBITDA and working capital [22] Business Line Data and Key Metrics Changes - In the A&G segment, there was a 2% ACV growth, with a subscription mix now at 93% compared to 81% last year [7][8] - The Intellectual Property segment's recurring revenue was flat year-to-date, but showed a 3% improvement in organic growth rate compared to the full year of 2024 [9] - The Life Sciences and Health segment returned to 2% ACV growth, driven by new product introductions and AI integration [11] Market Data and Key Metrics Changes - The company secured over 100 contracts for its new content subscription framework, indicating strong market demand [8] - Renewal rates in the A&G segment were strong, with 90% of global subscriptions successfully renewed through October 27 [8] - The overall patents in force in core markets are expected to grow, indicating a potential recovery in the IP market [60] Company Strategy and Development Direction - The company is focused on executing its value creation plan, emphasizing product and AI development to drive organic growth [6][14] - There is a commitment to optimizing the business model by increasing the core subscription and recurring revenue mix [7] - The company is streamlining its business model by exiting non-core areas and focusing on strategic alternatives [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning the IP segment to sustainable growth under new leadership [9][34] - The company anticipates continued acceleration in organic annual contract value and recurring organic growth in the upper half of its guidance range [24] - There is optimism regarding the impact of AI on future growth, with expectations of a market recovery in the coming years [60] Other Important Information - The company has completed $150 million in share repurchases year-to-date and paid down $100 million in debt [5][23] - The company expects to maintain a balanced capital allocation strategy while investing in product innovation [30] Q&A Session Summary Question: Insights on the patent renewal business and competitive landscape - Management noted that the patent and trademark renewal service declined by about 3% last year but is now flat year-to-date, with expectations for improvement under new leadership [34] Question: Updates on the value creation plan and new innovations - Management highlighted the introduction of new AI-enabled products and a renewed focus on product innovation as key components of the value creation plan [42] Question: Impact of large ebook transactions on revenue and EBITDA - Multiple large ebook transactions positively impacted revenue in Q3, with expectations for a slower decline in disposals than previously anticipated [46][68] Question: Trends in the IP market and catalysts for recovery - Management indicated that the overall patents in force are expected to grow, with AI innovation likely to boost renewal volumes in the coming years [60] Question: AI initiatives and proprietary content - The majority of AI innovations support information services, with significant proprietary data being utilized to enhance product offerings [62]

Clarivate (CLVT) FY Conference Summary Company Overview - **Company**: Clarivate (CLVT) - **Industry**: Information services, workflow solutions, particularly in university, pharmaceutical, and legal sectors Key Points and Arguments Divestiture Plans - Clarivate is evaluating options to sell its IP business segment and expects to communicate the outcome by year-end results in February [3][5] - Maroon Murad will join as president of the IP segment effective September 8, indicating a commitment to innovation and growth in this area [4] Value Creation Plan (VCP) - The VCP launched in 2024 is on track, with measurable progress across key initiatives [7] - Annual Contract Value (ACV) and renewal rates are increasing, with 88% of revenue now from subscription and recurring sources, up from 80% last year [8][12] - Major operational changes in the sales organization have been completed, enhancing customer engagement and retention [9][10] Financial Metrics - Organic recurring revenue mix is currently at 88%, expected to stabilize at 84% for the full year due to disposals [12][14] - The company aims for mid-single-digit organic growth in the long term, with expectations of returning to a 3-4% growth rate in the A and G segment [29][68] AI Integration and Innovation - Clarivate has launched 10 AI-powered products and is aggressively introducing new AI capabilities across its segments [10][11] - The company has established an AI innovation center of excellence, with 4,800 academic institutions currently using its AI solutions [52][58] - AI is seen as a significant growth driver, particularly in the IP business, as more inventions seek patent protection [39][41] Segment Performance - **A and G Segment**: 93% of the A and G business is recurring with a 96% renewal rate. The introduction of subscription-based products is expected to drive growth [20][21][23] - **IP Business**: Experienced 1.5% growth in the first half of the year, with expectations of mid-single-digit growth in the long term [36][38] - **Life Sciences and Healthcare (LS and H)**: Stability in R&D spending and improved renewal rates for the Cortella suite of products. New product launches are anticipated to drive growth [47][50] Capital Allocation Strategy - Clarivate expects to generate mid-$300 million in free cash flow, focusing on share repurchases and debt repayment rather than M&A in the near term [65][66] - The company aims to reduce leverage over time while capitalizing on attractive stock value [66][67] Long-term Growth Outlook - Clarivate anticipates organic growth rates to align with industry growth rates, with a focus on increasing the proportion of subscription revenue [68][70] Additional Important Insights - The company is optimistic about growth opportunities in both developed and developing markets, fueled by continuous innovation and AI advancements [27][28][30] - Clarivate's strategic focus on enhancing its product offerings and customer engagement is expected to yield positive results in the coming years [11][19][50]

Financial Data and Key Metrics Changes - Q2 2025 revenue was $682 million, with core sales increasing by 5.6% year-over-year, aided by customer buying ahead of expected price increases [8][16] - Adjusted EBITDA margin was 12.4%, up 240 basis points from the previous year, supported by G&A productivity improvements [9][16] - Adjusted EPS for Q2 was $0.26, an increase of $0.15 compared to the same quarter last year [16][18] - Free cash flow for Q2 was $76 million, down from the previous year due to higher working capital [26] Business Line Data and Key Metrics Changes - Equipment and consumables revenue grew approximately 7%, while specialty products increased just shy of 5% [9][22] - Specialty Products and Technology segment saw core revenue growth of 7.2%, with adjusted operating margin improving to 13.5% [22] - Equipment and Consumables segment reported a 7.3% increase in core sales, with diagnostics showing mid-single-digit growth in North America [24] Market Data and Key Metrics Changes - Double-digit growth was observed in Latin America, Indo-Pacific, and Middle East and Africa regions [14] - The dental market remains stable, with no significant improvement or deterioration expected in the second half of 2025 [28][32] Company Strategy and Development Direction - The company is focused on a value creation plan that includes accessing untapped growth in core markets, new product innovation, and strategic acquisitions [11][12] - Plans to expand manufacturing in China to support local demand, with a new site in Suzhou [14][15] - Continued investment in R&D, with a 14% increase in the first half of 2025, leading to several new product launches [13] Management's Comments on Operating Environment and Future Outlook - Management noted that macroeconomic conditions have improved slightly, with low unemployment and rising consumer confidence [36][39] - The company anticipates a stable dental market and expects to offset tariff impacts through supply chain actions and cost reductions [29][30] - Future guidance was updated to reflect core revenue growth of 3% to 4% and adjusted EPS of $1.5 to $1.15 [10][27] Other Important Information - The company repurchased $82 million worth of shares in Q2, continuing a $250 million two-year repurchase authorization [27] - The adjusted tax rate for the year is now forecasted at 33%, improved due to strong U.S. profits [30] Q&A Session Summary Question: Was the strength seen across the portfolio surprising? - Management noted that Q2 macro conditions were incrementally better than Q1, with strong growth in orthodontics and consumables [36][38] Question: What drove the outsized growth in brackets and wires? - Increased investment in sales and marketing and a potential shift from clear aligners to brackets and wires contributed to growth [42] Question: How is the China market performing ahead of VBP? - The brackets and wires business in China was down 20-30% year-over-year in the first half, but robust growth is expected in Q4 post-VBP [51] Question: What is the outlook for Spark's profitability? - The company expects Spark to turn EBIT positive in the second half of 2025, with consistent unit cost reductions [59] Question: How are dental practices responding to price increases? - Price increases have been modest and well-received, with a delay in equipment purchases noted across the market [90][91] Question: What is the impact of tariffs on margins? - Tariff costs in Q2 diluted margins by approximately 60 basis points, with expectations of $15 million to $20 million in tariff costs in the second half [80]